VFA
HAE icon

Virtus Fund Advisers’s Haemonetics HAE Stock Holding History

Virtus Fund Advisers’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,358
Closed -$112K – 116
2024
Q2 		$112K Buy
1,358
+52
+4% +$4.57K 0.44% 17
2024
Q1 		$111K Buy
1,306
+120
+10% +$9.42K 0.39% 26
2023
Q4 		$101K Hold
1,186
– – 0.63% 15
2023
Q3 		$106K Buy
1,186
+155
+15% +$13.8K 0.75% 16
2023
Q2 		$87.8K Hold
1,031
– – 0.62% 23
2023
Q1 		$85.3K Hold
1,031
– – 0.6% 25
2022
Q4 		$81.1K Buy
+1,031
New +$82.9K 0.58% 23
2014
Q3 		– Sell
-4,441
Closed -$157K – 1480
2014
Q2 		$157K Buy
+4,441
New +$148K ﹤0.01% 1090

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Virtus Fund Advisers's HAE Position: Q3 2024 in Review

Virtus Fund Advisers sold out of Haemonetics (HAE) in Q3 2024, closing a stake of 1,358 shares — an estimated $112K sold.

Virtus Fund Advisers first reported a position in HAE in Q2 2014 and held it in 8 quarters. The position peaked at $157K in Q2 2014. 306 funds tracked by Wall St. Rank hold HAE as of Q3 2024.

  • Virtus Fund Advisers reported no remaining Haemonetics position as of Q3 2024 after selling out during the quarter.
  • Virtus Fund Advisers sold 1,358 Haemonetics shares in Q3 2024, an estimated $112K.
  • Virtus Fund Advisers first reported a position in Haemonetics in Q2 2014 and held it in 8 quarters.
  • Virtus Fund Advisers's Haemonetics position peaked at $157K in Q2 2014.
  • 306 funds tracked by Wall St. Rank held Haemonetics as of Q3 2024.

Based on Virtus Fund Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.